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O B J E C T I V E :  To describe the characteristics and risk of 
bacille Calmette-Guérin (BCG) vaccine related disease in 
human immunodefi ciency virus (HIV) infected infants.
M E T H O D S :  Systematic literature review of articles pub-
lished from 1950 to April 2009 in the English language. 
We identifi ed all microbiologically confi rmed cases of 
disseminated BCG disease in vertically HIV-infected 
children reported in the literature. 
R E S U LT S :  Sixteen observational studies and 11 case re-
ports/series were included. Observational studies suf-
fered from high rates of loss to follow-up and death. 
Loco-regional BCG disease was reported in both HIV-
infected and non-infected children. Disseminated BCG 
disease was reported only in children with immunodefi -
ciency and only in studies employing sophisticated labo-
ratory techniques. Sixty-nine cases of disseminated BCG 
were identifi ed in the literature: 47 cases were reported 
in six observational studies, the majority (41/47) from 
the Western Cape of South Africa. A Brazilian cohort 
study reported no cases of disseminated BCG amongst 
66 HIV-infected children observed over a 7-year period. 
A recent South African surveillance study reported 32 
cases of disseminated BCG over a 3-year period, esti-
mating the risk of disseminated BCG to be 992 per 
100 000 vaccinations in HIV-infected children. Few 
cases of severe disseminated TB were reported in the co-
hort studies among HIV-infected children vaccinated 
with BCG. 
C O N C L U S I O N :  Data on the risk of BCG vaccination in 
HIV-infected children are limited. Targeted surveillance 
for BCG complications employing sophisticated diag-
nostic techniques is required to inform vaccination 
policy.
K E Y  W O R D S :  BCG; HIV; disseminated; review
FOR MORE THAN 30 YEARS, bacille Calmette-
Guérin (BCG) vaccinations have been administered 
to newborns in settings where tuberculosis (TB) is en-
demic.1 BCG is the only vaccine currently available 
for TB, and it is effi cacious, cost-effective and requires 
only one encounter with the infant.2,3 It is also con-
sidered safe in healthy infants.1 Vaccine site ulcera-
tion and scar formation are common and accepted to 
be a normal response to vaccination.4 Loco-regional 
adverse reactions such as large ulcers (>10 mm di-
ameter) and regional adenitis are usually self-limiting 
and occur in 100–400 per million vaccinations, with 
the risk varying with vaccine strain, dose, bacillary 
load, route of administration and population charac-
teristics.1,4,5 Disseminated BCG disease from the live 
attenuated vaccine is a rare but potentially fatal com-
plication, reported in less than 5 per million vaccina-
tions, almost exclusively in immunocompromised 
hosts.6 Previously, those considered at risk were chil-
dren with rare congenital immunodefi ciency, but there 
has been growing concern that human immunodefi -
ciency virus (HIV) infection would increase the risk 
of disseminated BCG disease.7 As countries now ex-
periencing the greatest burden of TB also have high 
rates of HIV infection,8 the safety of BCG vaccina-
tion programmes in high-prevalence HIV countries is 
being reconsidered.
The World Health Organization (WHO) fi rst ad-
dressed the safety of BCG in HIV-infected children in 
1987, and recommended until recently that asymp-
tomatic (presumed immunocompetent) HIV-infected 
children should receive the vaccine.6,9,10 In 2007, the 
WHO revised this policy to recommend that HIV-
i nfected infants should not receive BCG even if asymp-
tomatic.11 This major policy reversal was prompted by 
data from South Africa and Argentina that suggested 
that the risk of disseminated BCG disease was mark-
edly increased in children with asymptomatic HIV 
infection at the time of vaccination.12,13 However, the 
risks associated with BCG vaccine in HIV-infected 
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children have not been established, and disparate 
fi ndings have been published for many other at-risk 
populations.14–16 
The implementation of the current WHO policy 
has important public health implications and major 
programmatic challenges, especially in resource-poor 
communities that are endemic for TB-HIV. These 
challenges are recognised by the WHO and have re-
cently been outlined by the BCG Working Group of 
the International Union Against Tuberculosis and 
Lung Disease (The Union).11,17 It is diffi cult to iden-
tify asymptomatic HIV-infected infants for selective 
withholding of BCG vaccination from the much 
larger group of HIV-exposed but non-infected infants 
for whom BCG is still indicated. Indeed, this is often 
impossible in the context of Expanded Programme 
on Immunization (EPI) activities in resource-limited 
settings, where the greatest burden of mother-to-child 
transmission of HIV and TB exist. Delaying BCG 
vaccination until HIV infection status is known, how-
ever, increases the risk of severe disease due to Myco-
bacterium tuberculosis for the HIV-exposed but non-
infected infant, and possibly for the HIV-infected 
infant as well. Prospective data on the protective effi -
cacy of BCG against TB are lacking in HIV-infected 
infants but will be critical to informing policy, includ-
ing in settings where early antiretroviral treatment 
(ART) is available. 
In the present review, we describe the characteris-
tics of all reported cases of disseminated BCG disease 
in HIV-infected children, and evaluate if it is possible 
to arrive at a valid estimate of the risk of BCG dis-
ease in HIV-infected infants.
METHODS
Search strategy
PubMed, MEDLINE and publications on the WHO 
website were searched for articles published between 
1950 and April 2009 in English. EMBase (1980–April 
2009) and The Cochrane Library were also subse-
quently searched using the same strategy. Broad 
search terms were used to maximise the sensitivity of 
the search, as BCG disease in HIV is a rare outcome: 
‘(bacille Calmette Guerin OR BCG) AND HIV’ and 
‘(bacille Calmette Guerin OR BCG) AND dissemi-
nated’. Bibliographies of retrieved publications were 
also reviewed for relevant citations. Endnote X was 
used to manage citations and Stata 10 (Stata Corp, 
College Station, TX, USA) to calculate summary 
statistics. 
Inclusion criteria
Original data published in English language were in-
cluded. Case reports and series of microbiologically 
confi rmed disseminated BCG in HIV-infected infants 
were identifi ed and included to inform the clinical 
presentation and prognosis of disseminated BCG dis-
ease in HIV-infected children. To estimate risk, exper-
imental and observational studies that measured both 
the exposure to HIV infection and BCG vaccination 
and the outcome of BCG disease were included. Stud-
ies were only included if the infant’s HIV infection 
was reported to be the result of mother-to-child trans-
mission, and BCG vaccination was given as a single 
dose in the newborn period. Observational studies 
that measured BCG vaccination status solely by scar 
were excluded because of the possibility of ascertain-
ment bias (HIV-infected children are less likely to form 
a scar from vaccination).18
Given that many studies have been published from 
a few geographic areas, it was possible that a case of 
disseminated BCG disease might have been reported 
by more than one publication; possible duplicate data 
were identifi ed by reviewing the population sampled, 
sampling period and contributing authors. 
Exposure and outcome defi nitions
Infants born to mothers with HIV infection were 
considered HIV-exposed. Infants born to mothers 
without HIV infection were considered non-HIV-
e xposed. Confi rmation of HIV status for infants aged 
<18 months required antigen-based testing such as 
polymerase chain reaction (PCR). Infants were con-
sidered BCG-vaccinated if they received BCG (either 
subcutaneous or intradermal) in the newborn period, 
confi rmed by scar or vaccination record.
We aimed to standardise the defi nition of BCG 
disease using the Revised Paediatric Classifi cation for 
BCG disease:19
Local disease: an abscess >10 mm diameter or severe 
scar ulceration.
Regional disease: involvement of the ipsilateral lymph 
node.
Distant disease: involvement of any site beyond the 
ipsilateral node.
Disseminated disease: demonstration of BCG at a 
distant site (and/or demonstration of BCG in blood 
or bone marrow by culture/PCR) combined with a 
systemic syndrome compatible with mycobacterial 
disease (fever, weight loss, anaemia, death).
BCG immune reconstitution infl ammatory syndrome 
(IRIS) was defi ned as BCG disease (local, regional, 
distant or disseminated) occurring within 3 months 
of commencing ART. The measure of BCG disease 
used by each study was classifi ed as clinical, myco-
bacterial culture with biochemical speciation, or 
BCG-specifi c PCR.
Cases of TB disease were reported, as these may 
represent missed BCG disease without mycobacte-
rial speciation. The rate of microbiologically con-
fi rmed severe TB (TB meningitis or disseminated TB) 
in BCG-vaccinated children also informs effi cacy 
estimates. 
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RESULTS
A total of 1035 publications were identifi ed using the 
broad search strategy in PubMed, MEDLINE and the 
WHO website. No further studies were identifi ed in a 
subsequent search of EMBase or The Cochrane Li-
brary. All abstracts were read, and 215 full-text pub-
lications were sourced and reviewed, identifying 88 
original studies or reports. Sixteen limited reviews 
were identifi ed, but these were not systematic and in-
cluded studies of poor quality with exposures other 
than HIV from vertical transmission.9,20–34 
Microbiologically confi rmed cases of disseminated 
BCG are shown in Table 1. Sixteen observational stud-
ies met the inclusion criteria (Figure), including 10 co-
hort studies (Tables 2 and 3) and six cross-sectional 
and surveillance studies (Table 4).12–14,18,19,36,37,39,49–56 
Studies with longitudinal follow-up demonstrated high 
rates of death and loss to follow-up, especially among 
the HIV-exposed/infected infants (see footnote to Ta-
ble 3). Two publications authored by Hesseling et al. 
reported the same six cases of disseminated BCG: the 
2006 report included loco-regional disease, while the 
2007 report allowed for a population-based estimate 
of risk; both are included in the review.13,19 
Clinical features of disseminated BCG disease
in HIV-infected children
Sixty-nine cases of disseminated BCG disease con-
firmed by culture or PCR were reported in HIV-
i nfected children; 47 in six observational stud-
ies,12,19,36,37,39,56 15 in four case series35,40,42,43 and seven 
in single-case reports.21,22,44–48 Clinical details are sum-
marised in Table 1; clinical details were not available 
for the 32 cases reported by Hesseling et al.56 All chil-
dren received BCG in the neonatal period. The BCG 
strain varied depending on national policy, with the 
Danish strain being the most commonly reported. At 
least two cases of disseminated disease presented after 
commencing ART.36,57 The median age at onset of BCG 
disease was 8 months (range 3–35) in the 22 cases in 
whom this was reported. Of the 36 cases with re-
ported outcome, 29 (81%) died. Time to death from 
diagnosis of BCG disease was reported in 17 of the 
29 deaths, and ranged from a few days to 18 months. 
Among the 17 deaths where time to death was re-
ported, those receiving antimycobacterial treatment 
(12/17) had a mean survival of 5.9 months compared 
to 0.18 months for those untreated (P = 0.05). Seven 
children with disseminated BCG survived. The treat-
ment of fi ve survivors reported by Bologna et al. is un-
clear, with ‘survival improving with the use of highly 
active antiretroviral treatment’ (HAART).42 The 
other two survivors received antimycobacterial treat-
ment and ART.19,36
Risk of loco-regional BCG disease 
in HIV-infected children
Loco-regional BCG complications were observed in 
both HIV-infected and non-HIV-infected children. In 
total, the 15 observational studies (Tables 2, 3 and 4) 
reported 235 cases of loco-regional disease; 103 cases 
of loco-regional disease occurred in HIV-infected in-
fants (61 cases of loco-regional IRIS), 45 among HIV-
exposed but non-infected infants and 87 among non-
HIV-exposed and non-infected infants. A pooled risk 
was not calculated owing to the different vaccine 
strains used in these studies. De Souza et al.14 and 
Rabie et al.50 both reported complications exclusively 
in HIV-infected children, while Chokephailbulikt 
et al.49 reported complications only in HIV-exposed 
non-infected children. Hesseling et al. reported two 
children with loco-regional BCG disease who also 
had M. tuberculosis isolated from gastric aspirate 
(combined disease).37 Of note, the Zairian cohort 
study of Ryder et al. reported a large number of local 
Figure Results of the search and review process. WHO = 
World Health Organization; BCG = bacille Calmette-Guérin; 
HIV = human immunodefi ciency virus; PCR = polymerase 
chain reaction.
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complications, with an overall rate of 6%.52 Twenty-
fi ve cases of regional adenitis (12/474 HIV-exposed 
infants, 13/616 non-HIV-exposed, relative risk [RR] 
1.2, 95% confi dence interval (CI) 0.6–2.6) and 44 
cases of fi stulisation (18 in HIV-exposed infants, RR 
0.9, 95%CI 0.5–1.6) were reported, with no statisti-
cal difference by HIV exposure status. Data are limited 
on outcome for loco-regional BCG disease in HIV-
i nfected children. Hesseling et al. reported 11 cases of 
loco-regional BCG complications, of which six died.19 
They reported that ART for infants with local and 
disseminated disease was associated with signifi cantly 
improved survival.
Risk of disseminated BCG disease 
in HIV-infected children
A total of 49 cases of disseminated BCG were re-
ported in the observational studies (Tables 2, 3 and 
4), 47 in HIV-infected infants and two cases in chil-
dren with other immunodefi ciencies. Table 5 sum-
marises the risk of disseminated BCG for various ex-
posure groups.
Of the 47 cases of disseminated BCG disease in 
HIV-infected children reported in observational stud-
ies, 41 (87%) were reported by Hesseling et al. from 
the Western Cape Province of South Africa. In their 
earliest study, they speciated 183 mycobacterial iso-
lates from 49 HIV-infected children using PCR.37 
M. bovis BCG was identifi ed in fi ve children, with 
three having loco-regional disease and two dissemi-
nated disease. The 2006 study similarly involved lab-
oratory surveillance, enrolling 466 children with my-
cobacterial isolates, of which 108 were HIV-infected.19 
Eight children were identifi ed to have disseminated 
disease (six HIV-infected, two with other immuno-
defi ciencies). The 2007 prospective study included data 
Table 5 Rates of disseminated BCG in studies with well-defi ned denominator populations and microbiologically confi rmed 
BCG disease
First author, year, reference Setting
Denominator
Cases
n
Rate (95%CI)
per 100 000*Population n
ART-naïve HIV-infected children
 Hesseling, 200956 South Africa Estimated number of HIV+ 
children vaccinated with 
Danish BCG (using measured 
vertical transmission rates)
3226 32  992 (567–1495)
 Hesseling, 200713 South Africa Estimated number of HIV+ 
children vaccinated with 
Danish BCG, assuming:
5% vertical transmission 1898  7  369 (148–758)
10% vertical transmission 3798  7  184 (74–379)
15% vertical transmission 5696  7  122 (49–253)
 De Souza, 200814 Brazil Infants with vertically acquired 
HIV infection immunised 
with Rio de Janerio BCG 
66  0    0 (0–5435)
 Fallo, 200538 Argentina Infants with vertically acquired 
HIV infection immunised 
with BCG
310  4 1290 (352–3270)
HIV+ receiving ART
 Rabie, 200850 South Africa HIV-infected infants 
commenced on ART early 
(asymptomatic) or delayed 
(symptomatic)
417  0    0 (0–881)
 Nuttal, 200836 South Africa Symptomatic HIV-infected 
infants commenced on ART
352  1  284 (7–1573)
 Puthanakit, 200651 Northern 
Thailand
Symptomatic HIV-infected 
children admitted to hospital 
commenced on ART
153  0    0 (0–2382)
Special clinical situations
 Waddell, 200139 Zambia Children admitted with clinical 
AIDS, confi rmed HIV+
488  1 0.2% (0–1%)
 Hesseling, 200619 South Africa Children investigated for 
mycobacterial disease with 
mycobacterial isolates
All children 466  8 1.7% (1–3%)
HIV+ children 108  6 5.5% (2–12%)
 Hesseling, 200337 South Africa HIV+ children with 
mycobacterial isolates 
49  2 4% (0.5–14%)
* 95% binomial proportion CIs are reported, with one-sided estimates (97.5%CI) reported if numerator was 0.
BCG = bacille Calmette-Guérin; CI = confi dence interval; ART = antiretroviral treatment; HIV = human immunodefi ciency virus; HIV+ = HIV-positive; AIDS = 
acquired immune-d efi ciency syndrome.
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from the 2006 study (laboratory surveillance), and 
also employed clinical surveillance, reporting a fur-
ther case of disseminated disease.13 The denomina-
tor (HIV-i nfected children immunised with BCG) was 
estimated using population data. Rates of HIV infec-
tion among children were estimated using data on 
maternal HIV status and estimated HIV vertical 
transmission rates (5–15%); the BCG vaccine cover-
age rate was assumed to be 95%. The estimated risk 
of disseminated BCG was calculated for each year of 
observation, and ranged from 110–417 per 100 000 
HIV-infected children vaccinated with BCG. Pooled 
data for the 3 years of observation and calculated 
confi dence intervals are shown in Table 5. A recent 
study by the same authors expanded the surveillance 
for disseminated BCG to three hospitals servicing 
the Western Cape Province, and included measured 
(rather than estimated) vertical transmission rates to 
estimate the denominator.56 BCG vaccine coverage 
was based on census and health survey data and taken 
to be 98–99%. In total, 32 cases of disseminated BCG 
were reported, with a pooled risk of 992 per 100 000 
(95% CI 567–1495).
The Argentinean study of Fallo et al. reported four 
cases of disseminated BCG amongst 310 HIV-infected, 
BCG-vaccinated children (Table 4, clinical details in 
Table 1).12 Details of recruitment, duration of obser-
vation and numbers of lost to follow-up or deaths 
were not available for this retrospective study. These 
data are a subset of a larger study which included 64 
non-BCG-vaccinated HIV-infected children; however, 
measure of BCG vaccination status was unclear. Fifty-
one cases of TB (44 in those considered vaccinated) 
were reported, including 10 cases of disseminated TB 
or TB meningitis, with no difference in the rate be-
tween those considered vaccinated or not.58 TB was 
diagnosed clinically in most cases, and confi rmed by 
culture or PCR in 19 (37%) children.
In a Zambian study, Waddell et al. collected myco-
bacterial blood cultures from 736 children with clin-
ical AIDS.39 Mycobacteraemia was measured by 
culture and speciation using PCR. Of the 736 chil-
dren with clinical acquired immune-defi ciency syn-
drome (AIDS), 488 (66%) were confi rmed to be HIV-
i nfected and 387 of these had evaluable blood cultures 
and clinical histories (cultures were not evaluable in 
101 HIV-infected children, as they were blood culture-
positive for other bacteria or fungi). Ninety-eight 
per cent (378/387) were BCG-vaccinated (68 had 
been immunised by record but did not have a scar). 
Six HIV-infected children had positive blood cul-
tures for mycobacteria, with one of these speciated to 
M. bovis BCG.
BCG disease in HIV-infected children receiving ART
Three cohort studies reported BCG complications in 
children receiving ART.36,50,51 The ‘Children with 
HIV Early anti-Retroviral’ (CHER) study recruited 
415 BCG-vaccinated (Danish ID) HIV-infected in-
fants, allocating 292 to receive ART ‘early’ from week 
6 to week 12 (regardless of CD4 count), and 125 to 
receive ART ‘deferred’ when CD4 < 20%.50 In total, 
373 received ART, with 33 children developing re-
gional adenitis (rate 9%, incidence 11.2 per 100 
person-years). The risk of regional adenitis was much 
higher in those in the deferred arm (13/83, 16%) 
compared to the early treatment arm (13/250, 5%, 
odds ratio [ORs] 3.4, 95%CI 1.5–7.7, P = 0.004). 
Two children not receiving ART developed regional 
adenitis, with dissemination suspected but not proven 
in these children. In this study, BCG disease was mea-
sured clinically and was not microbiologically con-
fi rmed. Three children died (BCG disease possibly 
contributing to two deaths) and seven children had 
clinical pulmonary TB (one case of TB was confi rmed 
by culture). Nuttal et al. reported 20 cases of regional 
adenitis and one case of disseminated disease among 
352 BCG-vaccinated (Danish strain intradermal) chil-
dren with symptomatic HIV-infected receiving ART 
(rate 6%, 95%CI 3.7–8.0).36 Of 21 children with 
clinical BCG disease, 10 had microbiological assess-
ment, with seven of these confi rmed M. bovis BCG 
(including the child with disseminated disease). A 
Thai study reported two cases of loco-regional BCG 
disease among 153 children receiving ART (two fur-
ther cases were reported among children who received 
booster vaccination).51,59 These cases of BCG disease 
were confi rmed by PCR (isolated from regional node 
in one child and vaccine site ulcer in another child 
with associated regional adenitis). 
Few data were available on the management and 
outcome of BCG complications in HIV-infected chil-
dren receiving ART. Of the 21 cases of BCG disease 
reported by Nuttal (20 local, one disseminated), 10 re-
ceived antimycobacterial treatment, 15 had incision 
and drainage (some had both medical and surgical 
treatment), with eight managed conservatively.
DISCUSSION
The recommendation to withhold vaccination from 
HIV-infected children is based on concerns about 
disseminated BCG disease. In 2007, an estimated 
420 000 children became HIV-infected, most living in 
sub-Saharan Africa and acquiring infection vertically.57 
If HIV-infected infants continue to receive BCG vac-
cine and the risk of disseminated disease is 417 per 
100 000 vaccinations, about 1700 would develop dis-
seminated BCG globally every year.15 If the risk of 
disseminated BCG in HIV-infected infants is 992/ 
100 000, then 4000 would develop disseminated BCG 
disease annually. Our review found only 69 confi rmed 
cases of disseminated BCG disease in HIV-infected 
children reported in the literature. BCG disease is likely 
to be under-reported in resource-limited settings. Clin-
ical suspicion is low, as it is traditionally considered a 
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rare complication, with the clinical presentation of 
disseminated BCG disease similar to that of dissemi-
nated TB or severe sepsis. Studies demonstrating cases 
of disseminated BCG disease used either culture with 
biochemical speciation or PCR. Studies reporting no 
cases of disseminated disease had signifi cant limita-
tions: poor measures of exposure and outcome, short 
periods of observation, and high (or unknown) rates 
of death and loss to follow-up. 
The South African surveillance studies reported by 
Hesseling et al. have refocused attention on BCG vac-
cine policy, identifying a serious complication that 
has remained largely hidden among children with 
clinical TB or those who have died. The accuracy of 
estimated risk reported by these surveillance studies 
may be limited by study design. In the earlier study, 
several assumptions were made to estimate the num-
ber of HIV-infected children vaccinated (and at risk 
of complications), including vaccine coverage and 
vertical transmission rate.13 The more recent study 
used measured population rates of vertical transmis-
sion and vaccination and included a larger popula-
tion base.56 Both studies were conducted in the same 
region, but the estimates of risk obtained were signifi -
cantly different. These studies also employed PCR test-
ing to identify BCG disease. While likely to be very 
sensitive, it may also be that the demonstration of 
BCG at distant sites in the severely immunosuppressed 
child with AIDS (likely to have a systemic syndrome 
of fever, anaemia, weight loss and death) does not 
necessarily represent disseminated BCG disease; a 
transient ‘BCGaemia’ may be part of the normal vac-
cination process.59 The risk of disseminated BCG cal-
culated from the Argentinean study is similar to Hes-
seling et al.’s recent estimate.12,56 The Argentinean 
study was retrospective, and details of recruitment, 
measure of BCG vaccination status and number lost 
to follow-up were unclear for this cohort study. The 
study also reported a large number of cases of TB 
that were microbiologically confi rmed and may have 
included missed cases of BCG disease.
Based on Hesseling et al.’s recent estimate, at least 
100 HIV-infected infants would have to be followed 
to observe one case of disseminated BCG. The small 
sample (66 HIV-infected children) may explain why 
De Souza et al. reported no cases of disseminated 
BCG in the recent Brazilian study.14 HIV-infected 
children were aged 15 days to 10 years at recruit-
ment, which may have introduced bias, and local dis-
ease was aggressively treated with HAART and anti-
mycobacterial treatment, which may have halted 
progression to disseminated BCG disease. Nine chil-
dren died, and these may have included missed cases 
of disseminated disease. Among the causes of death 
attributed, one child died with gastroenteritis and 
clinical sepsis, one with pneumonia (unclear patho-
gen) and a further two of unclear aetiology. The strain 
of BCG used in Brazil is Moreau Rio de Janeiro, 
which may carry a different risk of disseminated dis-
ease than the Danish strain used in South Africa. 
There may also be population differences in disease 
susceptibility. Children from the Western Cape region 
of South Africa, for example, including those with 
HIV infection, may be more susceptible to mycobac-
terial disease than populations in Brazil or elsewhere. 
This region reported very high childhood TB inci-
dence, even before the HIV epidemic.60 Large cohort 
studies from other African populations in Zimbabwe, 
Malawi and Rwanda have not reported any cases 
of disseminated BCG disease amongst HIV-infected 
children who died.61–63 While these studies were 
not specifi cally designed to measure complications of 
BCG, they had large sample sizes (559 deaths among 
1147 HIV-infected infants were observed in the Zim-
babwe Vitamin A for Mothers and Babies Project [the 
ZVITAMBO cohort])64 and were conducted in set-
tings highly endemic for TB-HIV, with high rates of 
BCG coverage. Differing results and contextual fac-
tors have important implications for generalising the 
fi ndings of Hesseling et al.’s study and informing vac-
cination policy on a global scale.
Disseminated BCG is a catastrophic complication 
of vaccinating HIV-infected infants with a high case 
fatality rate. However, the cause of death in these 
children may not always be attributable to dissemi-
nated BCG disease. Several case reports describe chil-
dren with disseminated BCG disease who received 
antimycobacterial treatment and died several months 
later with Pneumocystis jirovecii pneumonia (PJP) or 
sepsis.22,44,46–48 In healthy children, BCG vaccination 
suppresses T-cell counts for up to 2 months.61,65 This 
reduction in T-cell count may cause rapid progression 
of immunosuppression in HIV-infected infants re-
ceiving BCG, increasing the risk of opportunistic in-
fection and mortality. Disseminated BCG disease is 
part of a continuum of BCG-related complications. 
While loco-regional disease in immunocompetent 
children is usually self-limiting, 6 of the 11 cases of 
loco-regional disease reported by Hesseling et al. 
died.19 Loco-regional disease in HIV-infected children 
may represent disseminated disease, or be associated 
with overwhelming immunodefi ciency and associated 
poor prognosis. Few studies report the outcome of 
loco-regional BCG disease in HIV-infected children. 
Risk of death from BCG disease appears to be mod-
ifi ed by antimycobacterial treatment and ART. This 
has important implications, as the WHO now recom-
mends that all HIV-infected infants aged <12 months, 
irrespective of clinical or immunological status, should 
receive ART.62,63 On the one hand, ART introduces 
the risk of IRIS (although the risk of IRIS is reduced 
with early ART).50 On the other hand, preservation 
of immune function in children receiving ART may 
modify the immune response to vaccinations and may 
reduce the risk of disseminated BCG. The early use of 
HAART will probably change not only the profi le of 
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disseminated BCG disease risk in HIV-infected infants, 
but also the risk of TB and, possibly, BCG effi cacy.66
Measuring the effi cacy of BCG in HIV-infected 
children is complex and beyond the scope of this 
r eview. These studies were not designed to measure 
the effi cacy of BCG in HIV-infected children, although 
some observations can be made. BCG is most protec-
tive of TB meningitis and disseminated TB, both of 
which have recognisable clinical presentation.3 Few 
cases of severe TB were reported in the longitudinal 
cohort studies, suggesting that BCG may still afford 
some protection in HIV-infected children. A recent 
study from South Africa found that HIV-infected in-
fants were at increased risk for all types of TB but did 
not fi nd a disproportionate increased risk of dissem-
inated TB or TB meningitis.67 While BCG-induced 
T-cell immune responses are much lower in HIV-
i nfected compared to HIV-exposed non-infected and 
non-HIV-exposed infants in the absence of HAART, 
the correlation with in vivo immunity remains un-
clear.68 Measured response to BCG varies between 
populations and between seasons.69 Vitamin D status 
also affects in vitro response to BCG, and vitamin D 
defi ciency may contribute to susceptibility to TB and 
BCG disease among children living in the Western 
Cape.70 The WHO has now directed that recording 
and reporting of childhood TB cases should be rou-
tine and should include HIV status whenever possi-
ble.71 This may provide an opportunity to examine 
the incidence of TB meningitis or miliary TB over 
time as a possible surrogate for BCG effi cacy in dif-
ferent settings of BCG coverage and HIV prevalence.
The present review has several important limita-
tions. Only studies published in English were included. 
Inclusion criteria were strict and only cases of dis-
seminated BCG confi rmed microbiologically were in-
cluded. While this ensured specifi city, sensitivity may 
have suffered. The defi nitions of HIV and BCG expo-
sure were also strict to refl ect current vaccination 
policy, and they allow for an estimate of risk that re-
lates to vaccination of infants in areas endemic for 
TB and HIV. A French study in which some children 
acquired HIV infection from blood transfusion was 
excluded.72 A Haitian cohort study was excluded as 
it reported children who received an inconsistent 
dose of BCG due to error.20 An Argentinean study in-
cluding children who received two doses of BCG was 
also excluded.73 Duplicate data may have also intro-
duced error, especially as a large number of cases of 
disseminated BCG was reported from the Western 
Cape Province. A surgical case series that reported 
two cases of disseminated BCG was excluded as it 
was based at the same hospital and had the same 
sampling period as Hesseling et al.’s 2007 report.74 
The review could also not fully take into account 
the different vaccine strain, bacillary load and route 
of administration which, in combination with popu-
lation differences and other therapies (such as ART), 
modify the risk of complications. It does, however, 
highlight issues for consideration in surveillance for 
BCG complications. Disseminated BCG has an onset 
between 3 and 36 months after vaccination. This has 
important implications for study design and clinical 
follow-up in settings where attendance usually drops 
after vaccinations are completed at 9 months. Clinical 
surveillance alone is unlikely to be sensitive or spe-
cifi c for disseminated BCG. The work of Hesseling et 
al. supports that active laboratory-based surveillance 
with appropriate speciation is essential to detect dis-
seminated BCG disease. While widespread use of lab-
oratory surveillance is unlikely to be cost-effective, 
targeted surveillance of ‘at risk’ groups may be. In the 
ZVITAMBO cohort, 63% of HIV-infected children 
died before their second birthday compared to 9% of 
HIV-exposed non-infected infants and 3% of non-
exposed infants.64 Eighty per cent of these deaths oc-
curred in the fi rst 6 months of life, making the accurate 
ascertainment of the cause of these deaths diffi cult. 
HIV-infected infants are at risk of BCG disease, 
but the degree of increased risk remains uncertain. 
Improved laboratory-based surveillance and more in-
cidence data of confi rmed cases are urgently needed. 
Improved population-based studies in areas outside 
sub-Saharan Africa are also required to inform vacci-
nation policy. BCG disease is associated with a high 
mortality in HIV-infected children, and early ART 
has a potential role in management and prevention. 
Most infants with HIV infection will continue to be 
vaccinated with BCG in the neonatal period, despite 
the current WHO recommendations. Early HIV diag-
nosis would facilitate implementation of the current 
WHO recommendations of withholding BCG from 
HIV-infected infants, but wider implementation of 
other, more readily available, recommendations, such 
as prevention of mother-to-child transmission of HIV, 
would also have a signifi cant impact on the burden of 
BCG disease. Improved knowledge of the potential 
effi cacy of BCG for HIV-infected and HIV-exposed 
infants in TB-endemic communities is critical to the 
risk-benefi t analysis needed to inform policy.
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R É S U M É
O B J E C T I F  :   Décrire les caractéristiques et les risques des 
maladies liées au vaccin bacille Calmette-Guérin (BCG) 
chez les nourrissons infectés par le virus de l’immuno-
défi cience humaine (VIH).
M É T H O D E S  :   Revue systématique des articles publiés 
dans la littérature entre 1950 et avril 2009 en langue an-
glaise. Nous avons identifi é tous les cas de bécégite dis-
séminée confi rmés par examen microbiologique signalés 
dans la littérature chez les enfants ayant subi une infec-
tion verticale par le VIH.
R É S U LTAT S  :   On a pu inclure 16 études observation-
nelles et 11 rapports de cas ou de séries. Les études ob-
servationnelles souffrent de taux élevés de pertes de suivi 
et de décès. La bécégite locorégionale a été signalée à la 
fois chez les enfants infectés ou non par le VIH. La bécé-
gite disséminée n’a été signalée que chez les enfants at-
teints d’immunodéfi cience et uniquement dans les études 
utilisant des techniques sophistiquées de laboratoire. 
On a pu identifi er dans la littérature 69 cas de bécégite 
disséminée ; 47 cas ont été signalés dans six études 
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o bservationnelles, la majorité (41/47) provenant du Cap 
de l’Ouest en Afrique du Sud. Une étude brésilienne de 
cohorte n’a pas signalé de cas de bécégite disséminée 
chez les 66 enfants infectés par le VIH et suivis pendant 
une période de 7 ans. Une étude de surveillance récente 
en Afrique du Sud a signalé 32 cas de bécégite dissémi-
née sur une période de 3 ans et estime le risque de bécé-
gite disséminée à 992 pour 100 000 vaccinations d’en-
fants infectés par le VIH. Un petit nombre de cas de 
tuberculose grave disséminée ont été signalés dans les 
études de cohorte parmi les enfants infectés par le VIH 
et vaccinés par le BCG. 
C O N C L U S I O N  :   Les données concernant les risques de la 
vaccination par le BCG chez les enfants infectés par le 
VIH sont limitées. Une surveillance ciblée des complica-
tions du BCG utilisant des techniques sophistiquées de 
diagnostic est nécessaire pour orienter la politique de 
vaccination. 
R E S U M E N
O B J E T I V O  :   Describir las características la enfermedad 
causada por la vacuna BCG en lactantes infectados por 
el virus de la inmunodefi ciencia humana (VIH) y calcu-
lar su riesgo de padecerla. 
M É T O D O S  :   Se llevó a cabo un análisis sistemático de 
los artículos científi cos publicados en inglés entre 1950 
y abril del 2009. Se detectaron todos los casos publica-
dos de enfermedad diseminada causada por la BCG, 
confi rmada bacteriológicamente, en niños con infección 
por el VIH adquirida por transmisión materno-fetal. 
R E S U LTA D O S  :   Se incluyeron 16 estudios de observa-
ción y 11 informes o series de casos. En los estudios de 
observación se encontró un alto índice de casos perdidos 
durante el seguimiento y de defunciones. Se observaron 
informes de enfermedad locorregional causada por la 
BCG en niños con infección por el VIH y en niños que no 
padecían esta infección. La becegeítis generalizada solo 
se comunicó en niños con inmunodefi ciencia y exclusiva-
mente en estudios donde se utilizaban técnicas sofi stica-
das de laboratorio. En las publicaciones se comuni caron 
69 casos de enfermedad diseminada, 47 notifi cados en 
seis estudios de observación, la mayoría (41 de 47) pro-
venientes del Cabo Occidental de Sudáfrica. En un estu-
dio de cohortes de 66 niños infectados por el VIH en el 
Brasil no se informó ningún caso de becegeítis gene-
ralizada durante un período de observación de 7 años. 
En un reciente estudio de vigilancia en Sudáfrica, se no-
tifi caron 32 casos de becegeítis diseminada en un lapso 
de 3 años y se calculó que el riesgo de padecer la enfer-
medad era de 992 por 100 000 vacunaciones de niños 
infectados por el VIH. Se comunicaron pocos casos de 
tuberculosis diseminada en los estudios de cohortes de 
niños con infección por el VIH que recibieron la vacuna 
antituberculosa.
C O N C L U S I Ó N  :   Existen pocos datos sobre el riesgo de 
la vacuna antituberculosa en niños infectados por el 
VIH. Se precisa instaurar una vigilancia dirigida de las 
complicaciones de la BCG, con técnicas diagnósticas 
sofi sticadas, a fi n de fundamentar las políticas sobre 
vacunación.
